文献速递治疗药物监测与药物基因组学抗菌药物管理特殊人群用药

囊性纤维化患者持续输注头孢洛扎-他唑巴坦并治疗药物监测

Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis.
PubMed 文献 · Am J Health Syst Pharm · 2019-01-01

报道一例30岁囊性纤维化女性患者,因急性肺加重伴多重耐药铜绿假单胞菌和产ESBL大肠埃希菌感染,采用头孢洛扎-他唑巴坦6g持续24小时静脉输注共10天,期间进行治疗药物监测确认暴露充分,临床缓解且无不良事件。

要点

  • 囊性纤维化患者可能存在 augmented renal clearance,需关注抗菌药物暴露不足。
  • 持续输注头孢洛扎-他唑巴坦6g/24h可用于多重耐药革兰阴性菌感染。
  • 治疗药物监测有助于确认持续输注方案的暴露充分性。

核心结论

  • 在囊性纤维化且伴 augmented renal clearance 的患者中,头孢洛扎-他唑巴坦持续输注方案可成功使用。

研究设计与样本

  • 个案报道:一例30岁囊性纤维化女性患者,因急性肺加重入院,体重降低且 presumed augmented renal clearance。

主要发现

  • 患者呼吸道培养为铜绿假单胞菌和产ESBL大肠埃希菌,药敏确认多重耐药。
  • 住院期间启动头孢洛扎-他唑巴坦6g持续24小时静脉输注,出院后继续,总疗程10天。
  • 持续输注最初36小时的治疗药物监测确认暴露充分。
  • 患者临床缓解,肺功能检查恢复至基线,未观察到药物不良事件。

关键数值与推荐

  • 头孢洛扎-他唑巴坦剂量为6g持续24小时静脉输注,总疗程10天。
  • 治疗药物监测覆盖持续输注最初36小时,确认暴露充分。

临床怎么用

  • 对囊性纤维化合并多重耐药革兰阴性菌感染且怀疑 augmented renal clearance 的患者,可考虑头孢洛扎-他唑巴坦持续输注并联合治疗药物监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The safe and effective use of ceftolozane-tazobactam delivered via continuous infusion in a cystic fibrosis (CF) patient with reduced body weight and presumed augmented renal clearance is reported. SUMMARY: A 30-year-old woman with CF was admitted for acute pulmonary exacerbations with positive respiratory cultures for Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Escherichia coli. Susceptibility testing confirmed multidrug resistance, and the patient was transitioned to ceftolozane-tazobactam for definitive therapy. A novel strategy of administering ceftolozane-tazobactam 6 g by continuous i.v. infusion over 24 hours was initiated during hospitalization and continued at discharge for a total of 10 days. Therapeutic drug monitoring over the first 36 hours of the continuous infusion confirmed adequate exposure. The patient had clinical resolution with return to baseline of pulmonary function tests and no noted adverse drug events. CONCLUSION: A continuous infusion regimen of ceftolozane-tazobactam was successfully used in a CF patient with augmented renal clearance.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Elizabeth Davis S, Ham J, Hucks J, et al. Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis. Am J Health Syst Pharm. 2019. PMID: 31361864. doi:10.1093/ajhp/zxz011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。